Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

18 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Therapeutic target biomarkers of patient-derived xenograft models of gastric-type cervical adenocarcinoma.
Kojima Y, Yoshida H, Okuya T, Okuma HS, Nishikawa T, Tanioka M, Sudo K, Noguchi E, Shimoi T, Tamura K, Tanase Y, Uno M, Ishikawa M, Arakaki M, Ichikawa H, Yagishita S, Hamada A, Fujiwara Y, Yonemori K, Kato T. Kojima Y, et al. Among authors: okuya t. Gynecol Oncol Rep. 2023 Nov 14;50:101302. doi: 10.1016/j.gore.2023.101302. eCollection 2023 Dec. Gynecol Oncol Rep. 2023. PMID: 38054200 Free PMC article.
Clinical outcomes in transplant-eligible patients with relapsed or refractory diffuse large B-cell lymphoma after second-line salvage chemotherapy: A retrospective study.
Yagi Y, Kanemasa Y, Sasaki Y, Sei M, Matsuo T, Ishimine K, Hayashi Y, Mino M, Ohigashi A, Morita Y, Tamura T, Nakamura S, Okuya T, Shimizuguchi T, Shingai N, Toya T, Shimizu H, Najima Y, Kobayashi T, Haraguchi K, Doki N, Okuyama Y, Shimoyama T. Yagi Y, et al. Among authors: okuya t. Cancer Med. 2023 Sep;12(17):17808-17821. doi: 10.1002/cam4.6412. Epub 2023 Aug 28. Cancer Med. 2023. PMID: 37635630 Free PMC article.
[Polatuzumab vedotin, bendamustine, and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma, including the outcome as a bridging treatment to CAR-T cell therapy or allogeneic hematopoietic stem cell transplant].
Morita Y, Yagi Y, Kanemasa Y, Sasaki Y, Ishimine K, Hayashi Y, Mino M, Ohigashi A, Tamura T, Nakamura S, Okuya T, Shimizuguchi T, Shingai N, Toya T, Shimizu H, Najima Y, Kobayashi T, Haraguchi K, Doki N, Okuyama Y, Ohashi K, Shimoyama T. Morita Y, et al. Among authors: okuya t. Rinsho Ketsueki. 2023;64(7):586-595. doi: 10.11406/rinketsu.64.586. Rinsho Ketsueki. 2023. PMID: 37544717 Japanese.
Utility of the frailty score for predicting prognosis and individualizing treatment intensity in elderly patients with diffuse large B cell lymphoma.
Yagi Y, Kanemasa Y, Sasaki Y, Goto S, Yamamura Y, Ishimine K, Hayashi Y, Mino M, Ohigashi A, Morita Y, Tamura T, Nakamura S, Okuya T, Shimoyama T. Yagi Y, et al. Among authors: okuya t. Ann Hematol. 2023 Jun;102(6):1485-1500. doi: 10.1007/s00277-023-05233-2. Epub 2023 Apr 28. Ann Hematol. 2023. PMID: 37115298
[Tisagenlecleucel for relapsed/refractory diffuse large B-cell lymphoma: real-world data from single institute experience].
Yagi Y, Kanemasa Y, Sasaki Y, Hayashi Y, Mino M, Kato C, Sakai S, Ohigashi A, Kanbara Y, Morita Y, Tamura T, Atsuta Y, Konuma R, Nakamura S, Wada A, Okuya T, Kageyama A, Murakami D, Nakashima S, Uchibori Y, Onai D, Hamamura A, Nishijima A, Omuro Y, Shingai N, Shimizuguchi T, Toya T, Shimizu H, Najima Y, Kobayashi T, Haraguchi K, Ohashi K, Doki N, Okuyama Y, Shimoyama T. Yagi Y, et al. Among authors: okuya t. Rinsho Ketsueki. 2022;63(10):1363-1372. doi: 10.11406/rinketsu.63.1363. Rinsho Ketsueki. 2022. PMID: 36351641 Japanese.
18 results